The overall goal of our Program is to conduct research on the causes, prevention, and therapy of gastrointestinal (GI) cancers.
We aim to have a strong translational component to our research that is enhanced by a close integration of the basic sciences with clinical and epidemiological research. With respect to etiological research, primary areas of interest include: a) assessing the roles of putative candidate genes, such as NAT 1 and 2 in colorectal cancer; b) studying prevalence and determinants of epigenetic events, such as hypermethylation of the estrogen receptor5 gene promoter, in colorectal tumor samples; c) characterizing population-based parameters for genes already accepted as causes of these cancers such as the mismatch repair genes in colorectal cancer; and d) how environmental factors may interact with these genetic factors. With respect to clinical research, an emerging them in our Program is to identify and understand why cancer patients or subjects with selected precursor lesions, such as Barrett's esophagus or colorectal polyps, have differential responses to therapeutic interventions. Increasingly, we are using molecular markers to develop a profile of patients who do or do not respond to a given therapy. This type of research involves a close collaboration between molecular biologists, clinicians, and epidemiologists. It has obvious and strong translational potential, since one goal, already being realized in some of our management of patients with Barrett's esophagus, is to tailor a given intervention to a given patient based on their likelihood of responding. In addition, we have strength in hepatitis research and hepatology, with four clinical research centers at USC (Hepatitis, Hepatitis C Virus, Alcohol, NIDDK). Given this existing expertise, we believe we have the potential for an active research program in liver cancer, and have established an infrastructure with monthly meetings to develop a research program in this area. To further enhance our already substantial research program in GI cancer, we are focusing on two near-term goals: 1) even better integration across the basic, clinical, and population-based sciences, and 2) strengthening our capabilities to apply high volume molecular technologies to ongoing and planned studies. Members of the GI Program currently have over $10,000,0000 in research support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-27S1
Application #
6577727
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-04-02
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications